Lipid Nanoparticle Assembly with Kinetic Size Control for Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing lipid nanoparticles (LNPs) are limited by poor reproducibility and inconsistent yield, with a lack of reliable processes to prepare LNPs with tunable sizes between 200 nm to 1200 nm, which affects in vitro and in vivo transfection efficiency.
Innovation Solution
A method involving kinetic control of nucleic acid/lipid nanoparticle assembly, including particle aggregation and growth arrest, to produce LNPs with defined sizes between 210 to 1200 nm, using a flash nanocomplexation technique and solvent polarity adjustments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for producing lipid nanoparticles are used, then in vitro and in vivo transfection efficiency is achieved, but reproducibility and yield consistency are poor
Solution Approach 1:
The patent applies parameter changes by systematically varying the N/P ratio (nitrogen to phosphate ratio), lipid composition, and nucleic acid concentration to optimize LNP formation. By controlling these parameters, the method achieves reproducible particle formation with consistent yield and size distribution, resolving the reliability issues of current methods
Solution Approach 2:
The patent employs feedback mechanisms through characterization techniques (such as dynamic light scattering for size measurement and nanoparticle tracking analysis) to monitor and adjust the LNP formation process in real-time. This feedback allows for optimization of transfection efficiency while maintaining reproducibility and yield consistency
2Adaptability or versatility
If sub-100 nm nanoparticles are generated in lyophilized form, then systemic delivery applications in vivo are enabled, but in vitro transfection efficiency in viral vector production cell lines is sub-optimal
Solution Approach 1:
The patent applies dynamics by creating a flexible LNP formulation system that can adapt particle size and composition based on the specific application requirements. The method enables dynamic adjustment of LNP characteristics to optimize for either in vitro transfection in cell lines or in vivo systemic delivery, achieving versatility across different applications
Solution Approach 2:
The patent uses parameter changes to tune LNP size, composition, and charge characteristics to match the requirements of different applications. By adjusting these parameters, the same basic LNP platform can achieve optimal performance both in vitro and in vivo, resolving the adaptability issue
3Reliability
If lipid nanoparticles in the range of 200 nm to 1200 nm are used, then in vitro and in vivo transfection efficiency may be improved, but reliable methods to prepare LNPs with tunable size in this range are lacking
Solution Approach 1:
The patent applies parameter changes by establishing a systematic approach to control LNP size within the 200-1200 nm range through adjustment of formulation parameters and processing conditions. This method provides reliable and reproducible preparation of LNPs with tunable size, enabling optimized transfection efficiency while ensuring manufacturing reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method yields stable and reproducible LNPs with superior transfection activity, improving cell and viral vector production quality and consistency, and simplifying transfection processes.
Implementation Method 1
reducing a polarity of the first solution from a dielectric constant of about 80 to about 45 to 60 to induce particle-size growth
Implementation Method 2
reversing the polarity of the second solution with a dielectric constant of about 65 to 80 to halt growth
Data Source
Figure 1A~1F
Figure 2A~2B
Figure 3A~3C
AI summary
Methods for preparing nucleic acid/lipid particles of an optimum particle size for efficient transfection of cells in vitro and in vivo local transfection are provided. The method is based on kinetic control of the nucleic acid/lipid nanoparticle assembly to prepare shelf-stable particles with defined sizes between about 50 nm and 1200 nm. The size-dependent characteristics of the nucleic acid/lipid particle-mediated transfection for the size range between 50 nm and 1200 nm also is provided.